ABSTRACT. It has generally been assumed that free unconjugated bilirubin gains access to the brain because of its lipid solubility. However, no measurements of the bloodbrain barrier permeability to free bilirubin exist. The aim of these experiments was to determine the blood-brain barrier permeability in the rat to free bilirubin using singlepass ( 
evidence indicates that the blood-brain barrier in humans is "tight" to macromolecules from an early stage in gestation (I).
It is now generally assumed that bilirubin crosses the bloodbrain barrier because of its lipid solubility, but there is no direct evidence for this contention. Although intramolecular hydrogenbonding masks polar groups and drastically reduces the aqueous solubility of bilirubin, especially when protonated as the acid, the molecule has very low solubility in nonpolar solvents such as ether (2). It is therefore not lipid soluble in the generally accepted sense. However, there is no doubt that it does have a high affinity for membrane lipids (2).
Diamond and Schmid (3) attempted to measure permeability of the blood-brain barrier to free bilirubin, and their study is generally cited as evidence for the "free bilirubin" hypothesis. However, these experiments did not include measurement of free bilirubin levels, and no attempt at quantitation was made.
The aim of our experiments was to quantify the transfer of bilirubin from blood to brain in the adult rat under conditions in which the relative proportions of free and albumin-bound bilirubin could be controlled and defined. The intracarotid bolus injection and in situ brain perfusion techniques were used. Evidence was obtained that the blood-brain barrier in the cerebral hemisphere of the adult rat is permeable to free bilirubin.
MATERIALS AND METHODS
Surgical Procedure. Studies were performed on adult male rats (Wistar strain), body wt 300-500 g. The rats had free access to a standard diet and water before surgery. Anesthesia was induced with halothane (Fluothane, ICI, Macclesfield, England), and maintained with sodium pentobarbitone (Sagatal, May & Baker Ltd, Dagenham, England) given initially as an intraperitoneal dose of 50 mg/kg body wt and thereafter intravenously at intervals. The left femoral artery and vein were cannulated, and arterial blood pressure was monitored continuously. Tracheostomy was performed and intermittent positive pressure ventilation instituted to maintain normal respiratory blood gas tensions. The right external carotid artery was exposed and clamped proximally during surgery. After ligation of the superior thyroid branch, it was retrogradely cannulated with polythene tubing (Portex, Hythe, England; outer diameter 0.8 mm, inner diameter 0.4 mm, length 15 cm) such that the tip was sited 2-4 mm distal to the bifurcation of the common carotid artery (Fig. la) . Care was taken not to interrupt flow to the right internal carotid at any time during surgery. Cannulae were kept patent with heparinized normal saline (2 IU sodium heparin/mL saline). In the case of in situ brain perfusion studies, the right common carotid artery was prepared for ligation by loosely encircling the artery with surgical thread (Fig. 16) . Surgery was performed on a heated operating table adjusted to maintain the animal's rectal temperature at 37.0 ? 0.5"C. Uptake studies were terminated by decapitation at 5 s in single-pass studies and at 60 s in brain perfusion [%]Bilirubin IX-a (sp act 6.2 Ci/mmol) was therefore specially prepared in collaboration with Amersham International's tritium-labeling service (TR5), as follows: crystalline bilirubin (Sigma Chemical Co., St. Louis, MO, cat. no. B4126) was purified by the method of McDonagh and Assisi (4), and used in the preparation of purified biliverdin as described by McDonagh and Palma (5). Purified biliverdin (4 mg dissolved in 1 mL methanol) was reduced with sodium boro-[3H]-hydride (0.6 mg solid, sp act 50 Ci/mmol), using an adaptation of the method described by Hutchinson et al. (6). The reagents were stirred in darkness under nitrogen at room temperature for 15 min. The reaction was halted with 10 mL glycine hydrochloride buffer, pH 2.8, and the product extracted with chloroform (10 mL x 3). Unincorporated tritium was removed by rotary evaporation after the addition of methanol. The product was pumped to dryness, sealed under argon in a glass ampoule, and transported to University College, London at -20°C. The [3H]bilirubin was retrieved in chloroform (15 mL) and reduced in volume to 0.8 mL before purification by thin-layer chromatography to remove the isomers 111-a and XIII-a! (Merck TLC silica gel (H) plates activated at 120°C for 60 min, and developed under argon with 1 % glacial acetic in analytical reagent chloroform). The bilirubin IX-a! band was eluted from the plate and extracted from the silica gel by washing with chloroform and centrifugation (X 3).
['HIBilirubin IX-a! (sp act 6.2 CiImmoL) was stored dry in aliquots of 0.25-2.0 nmol, under argon in sealed ampoules at -20°C in the dark.
Preparation of InjectateslPerfusates. Despite the optimal storage conditions used, the radiochemical purity of stock ['HI bilirubin had declined to 90% at the time of these experiments. After the addition of a 20-fold M excess of albumin to effectively bind all bilirubin, approximately 10% of the tritium activity remained dialyzable, indicating that it was not associated with bilirubin. A further purification process was therefore adopted immediately before its use. [3H]Bilirubin was retrieved from storage ampoules in a solution of 0.1 M sodium hydroxide and 5 mM EDTA, 0.4-0.8 mL. Human serum albumin (Kabi, Uxbridge, England), 0.8-1.6 mL, at pH 9 to prevent aggregation of bilirubin, was added in 20-fold M excess. The pH was adjusted to between 7.5 and 8.0 by addition of 0.5 M HCI. Unincorporated tritium was then removed by membrane dialysis against Ringer's saline, pH 7.5, gently agitated for 18 h at room temperature, in the dark. Visking tubing with a mol wt cutoff of 12 000-14 000 was used to dialyze 1 vol of albumin-bound bilirubin against 1 000 vol Ringer's saline. The use of albumin-binding to facilitate purification made it necessary to add a displacing agent to study free bilirubin uptake. The sulfonamide sulfadimethoxine (Madribon, Roche, Welwyn Garden City, England), which displaces bilirubin from its primary binding site on albumin, was used.
Sufficient dialyzed [3H]bilirubin was prepared to perform up to six experiments. Half was used to study the uptake of albuminbound bilirubin, and sulfadimethoxine was added to the remainder for free bilirubin studies. Sulfadimethoxine was added at a concentration of 10 mmol/L to injectates and 5 mmol/L to perfusates. The eficiency of the purification process and the amount of [%]bilirubin displaced from albumin by the sulfonamide were determined by centrifugation of samples of the injectatelperfusate, at the time of individual uptake studies, using Centriflo membrane cones (type CF25, Amicon Corp., Danvers, MA) operating below the maximum recommended relative centrifugal force of 1000 x g, at room temperature.
The pH of the solutions was measured before use and the concentration of bilirubin in injectates and perfusates was calculated from the known sp act of the ['Hlbilirubin used.
Experimental Procedure. Single-pass studies. The BUI for bilirubin was measured using an adaptation of the method originally described by Oldendorf (7). The injectate was delivered via a cannula placed retrogradely in the external carotid artery as described by Hardebo and Nilsson (8) rather than by direct puncture of the common carotid artery (Fig. 1 a) . The isotope composition of injectates was 0.4-1.0 @Ci ['Hlbilirubin, 0.1 -0.25 pCi [I4C] butanol, and 10 pCi 09"Tc as sodium pertechnetate. Butanol was used as a freely diffusible internal reference, almost completely extracted by the brain during a single passage, and sodium pertechnetate, which is nondiffusible, enabled correction for the background intravascular space. The osmolality of the injectates was 160-245 mosmol/kg, and the pH was 7.8-8.3. In the case of free bilirubin uptake studies, an intraperitoneal loading dose of 200 mg/kg of sulfafurazole was given to minimize the effect of any mixing between the injectate and rat plasma.
The injectate was infused as a 200 pL bolus over 1 s and decapitation performed after 5 s. Aliquots of the injectate and brain tissue samples from the frontal, parietal, and occipital lobes of the ipsilateral cerebral hemisphere were prepared for immediate y counting (Packard Auto-Gamma Spectrometer, model 3003, Packard, Cavesham, Berkshire, England), and, following digestion in soluene 350 (Packard), subjected to double-isotope liquid scintillation counting one wk later (Packard Liquid Scintillation System, Tricarb 2660). The BUI for albumin-bound and free bilirubin was calculated relative to the freely diffusible butanol reference from the respective ratios of tritium to I4C counts in brain and injectate samples. The contribution of residual isotope in the intravascular space represented by sodium pertechnetate was similarly calculated and subtracted from the overall BUI. Equation I was used to calculate the BUI for albumin-bound bilirubin. For free bilirubin studies, two furthgr corrections were necessary as described in Results.
['Hlbilirubin (brain)
In situ brain perfusion. The PA (mL/s/g) of the blood-brain Sodium pertechnetate served as an intravascular marker and Dalanine was used as a control for blood-brain bamer integrity. The pH of the perfusates was 7.5-8.0. The right common carotid artery was ligated immediately before infusion of the perfusate into the right external carotid artery (Fig. 16) . The rate of infusion was adjusted to provide a pressure greater than the animal's systolic blood pressure, thereby minimizing systemic blood flow to the right cerebral hemisphere. A flow rate of 5 mL/min and a perfusion time of 60 s, terminated by decapitation, were chosen. During the perfusion, systemic blood volume was maintained by withdrawing blood from the femoral artery at the same rate.
Brain
, and occipital (1 1.93 mL/s/g X lo2) cerebral perfusion flow. In the case of free bilirubin studies, two further corrections were necessary as described in Results.
C brain (T) T . Fpf. Cpf
Fpf, regional cerebral perfusion fluid flow (mL/s/g); Cpf, tracer concentration in the perfusate (dpm/mL); T, time duration of perfusion (s); and C brain (T), brain parenchymal tracer concentration at decapitation (dpm/g).
Statistics. Statistical significance was estimated by t test.
RESULTS
Single-pass studies. The mean arterial blood pressure, pH, and respiratory blood gas tensions were within the physiologic range and comparable in the two study groups (control injectate and injectate + sulfonamide) at the time of the experiments ( Table   1 ) .
Centrifugation of injectate samples demonstrated that, after albumin-binding and membrane dialysis, 4.1 + 2.4% (mean + SD, n = 14) of the tritium activity remained unincorporated. One h after addition of sulfadimethoxine to a portion of the injectate solution, the tritium activity in the filtrate increased by a further 16.5 * 4.2% (mean f SD, n = 18). This was attributed to displacement of bilirubin from albumin, and was not found to increase significantly with time over the subsequent 3 h. The total concentration of bilirubin in the albumin-bound control injectates was 493 + 157 nmol/L (mean + SD, n = 14), and in the sulfadimethoxine-treated injectates was 443 + 108 nmol/L (mean + SD, n = 18). The concentration of free bilirubin (mean f SD, n = 18) (Fig. 2) .
In situ brain perjiusion studies. The mean arterial blood pressure, pH, and respiratory blood gas tensions were within the physiologic range and comparable in the two study groups (control perfusates and perfusates + sulfonamide) at the time of the experiments ( Table 1) .
Centrifugation of perfusate samples demonstrated that after albumin-binding and membrane dialysis 3.3 + 1.1 % (mean + SD, n = 13) of the tritium activity remained unincorporated. One h after addition of sulfadimethoxine to a portion of the perfusate solution, the tritium activity in the filtrate increased by a further 17.3 + 6.9% (mean + SD, n = 12). This was attributed to displacement of bilirubin from albumin. The total concentration of bilirubin in the control perfusates was 67 + 19 nmol/L (mean + SD, n = 13) and in the sulfadimethoxine-treated perfusates was 65 * 18 nmol/L (mean + SD, n = 12). The concentration of free bilirubin displaced by the sulfadimethoxine was 11 + 4 nmol/L (mean + SD, n = 12). The measured PA value for bilirubin in the control perfusates was 1.91 a 0.98 x mL/s/g (mean + SD, n = 13). This could be accounted for by unincorporated tritium in the perfusate. The PA value for free bilirubin in sulfonamide-treated perfusates was calculated using the same corrections as described for the BUI, thus allowing for unincorporated tritium and the percentage of albumin-bound bilirubin shown in vitro to have been displaced in individual perfusates. There was no significant difference in the PA values obtained for the frontal, parietal, and occipital lobes, and a mean value was therefore calculated for the cerebral hemisphere as a BUI control injectate injectate +sulphonamide 
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whole. The cerebrovascular PA value for free bilirubin was 54.84 f 36.38 x mL/s/g (mean + SD, n = 13) (Fig. 3) .
The PA values for D-alanine, added to the control and sulfonamide-treated perfusates, were 5.02 -t 3.60 x mL/s/g (mean + SD, n = 13) and 5.80 + 4.06 X mL/s/g (mean + SD, n = 12) (NS), respectively. Although there are no other reported values for the PA of D-alanine for comparison, it would be expected to be low as the Km for L-alanine is 183 Kmol/mL (10). In contrast to other amino acids for which PA values have been determined, our value for D-alanine is, for example, approximately 20% of that quoted for phenylalanine (1 I).
DISCUSSION
Difficulties arising from the biochemistry of the bilirubin molecule and the limitations imposed by the experimental techniques used require discussion before interpretation of the results in the context of the newborn infant.
As commercially available radiolabeled bilirubin was of too low a sp act to meet the requirements of the study, tracer of the appropriate sp act had to be synthesized. Care is required with regard to ambient lighting and the pH of solutions containing bilirubin in view of bilirubin's chemical instability, ready isomerisation, photosensitivity, and low aqueous solubility. In vitro, and particularly at acid pH, the isomers bilirubin 111-a and XIIIa are formed by cleavage of bilirubin IX-a at the central methylene bridge with subsequent recombinations of the dipyrrole units. Crystalline bilirubin (Sigma Chemical Co., St. Louis, MO, cat. no. B4126) contains approximately 1-1.5% of the 111-a and 5-7% of the XIII-a isomers. These isomers accumulated further during the synthesis of ['Hlbilirubin, comprising approximately 15% of the product, and were removed by thin-layer chromatography. On retrieval of ['Hlbilirubin from storage vials and during preparation of the injectatelperfusate solutions, subdued lighting was used and an alkaline pH (> 9.0) was maintained until adjustment to pH 7.5-8.3 before purification and use. The high pH used was a necessary precaution in view of the low aqueous solubility of bilirubin in the physiologic range. At pH 7.4, the solubility of bilirubin dianion is 7 nmol/L (2). The radiochemical purity of stored [3H]bilirubin was documented to the limits of control perfusate perfusate +sulphommide the techniques available. The proportion of activity that remained dialyzable in the presence of a 20-fold M excess of albumin, which would effectively bind all bilirubin, was assumed to be unincorporated tritium, and attempts were made to remove this by prolonged membrane dialysis. Membrane filtration cones with a retention cutoff of 25 000 mol wt were chosen to assess the eficiency of this purification process and the displacing effect of the sulfonamide. They were used at low relative centrifugal force to avoid or minimize protein leakage.
The small percentage of apparently unincorporated tritium activity quantified in the control injectates and perfusates more than accounted for the uptake and permeability values observed in the control (albumin-bound bilirubin) experiments. The need for membrane dialysis to purify [3H]bilirubin immediately before use dictated the addition of a displacing agent to the injectate/ perfusate to provide free bilirubin. Any direct effect of the sulfonamide on blood-brain barrier permeability was excluded in the in situ brain perfusion studies by demonstration of the constancy of the D[U-14C]-alanine PA product in the control and sulfonamide-treated groups. D-alanine was used as a nontransported substance of a mol wt and low lipid solubility comparable to bilirubin.
After Oldendorfs original description of single-pass carotid bolus studies in the rat (7), the technique was modified. The traditional [3H]water reference was replaced by more diffusible substances, and the study duration of 15 s reduced. Butanol was used in these studies since it is largely extracted into brain tissue within a single capillary transit time (less than 1 s) and leaves the brain slowly at a rate of 1.1 %/s (12). To limit this efflux, which will tend to overestimate the BUI of the test substance, the time to decapitation was reduced to 5 s. A further advantage of reducing the study time is to minimize the effects of recirculation of tracer that occurs after 7-8 s (8). Some 96% of the injectate solution clears the brain by 2 s, and there is very little remaining at 5 s (8). Correction for residual tracer in the vascular space was made in these experiments by inclusion of nondiffusible 99mTc. A further important consideration when using single-pass techniques to study the uptake of albumin-bound substances is the degree of mixing that may occur between the injected bolus and circulating rat plasma. Pardridge et a/. (13) have documented that the upper limit for bolus mixing is 5.5%. To minimize the effect of bolus mixing in the free bilirubin uptake studies, an intraperitoneal loading dose of 200 mg/kg sulfafurazole was given.
The in situ brain perfusion technique used in the second series of experiments provides a quantitative measure of blood-brain barrier permeability. Initial studies using the in situ technique ( 9 ) endeavoured to maintain normal cerebral function and metabolism by using oxygenated perfusates containing glucose. Such precautions are unnecessary for short duration perfusions of one hemisphere. Greenwood el al. (14) have demonstrated maintenance of blood-brain barrier integrity for up to 30 min during in situ perfusion of the whole brain with a solution containing the metabolic inhibitor 2,4-dinitrophenol.
The single-pass and in sitzl perfusion experiments both demonstrate a significant permeability of the microvasculature of the adult rat cerebral hemisphere to unbound bilirubin. The methodology is unsuitable for studying areas of the brain such as the basal ganglia and cerebellum, but regional values were obtained from the frontal, parietal, and occipital lobes. In neither set of experiments was there any significant difference between the uptakes of these three brain regions. The BUI observed for free bilirubin of 28.5 + 9.3% is considerably greater than that reported for aqueous soluble polar compounds such as mannitol, but very much less than that for highly lipid-soluble compounds such as propranolol and caffeine, which attain BUI in excess of 70%.
Similarly, the PA value for free bilirubin of 54.84 + 36.38 x mL/s/g indicates that the permeability of the rat bloodbrain barrier to free bilirubin is significant because it approaches that of molecules such as antipyrine with a PA in the region of
